Fungal Immunomodulatory Proteins Mitigate Chemotherapy Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chemotherapy for cancer and proliferative diseases often comes with severe adverse side effects such as myelosuppression, mucositis, and osteoporosis, which current treatments fail to adequately mitigate, impacting patients' quality of life and treatment efficacy.
Innovation Solution
The use of fungal immunomodulatory proteins (FIPs), such as FIP-gts and FIP-fve, in combination with chemotherapeutic agents like Docetaxel, to administer before, during, or after chemotherapy to reduce or prevent these adverse side effects by enhancing immune response and protecting tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutic agents are used to treat cancer, then tumor cells are killed, but severe adverse side effects occur such as myelosuppression, mucositis, and osteoporosis
Solution Approach 1:
FIP acts as an intermediary substance that mediates between the chemotherapeutic agent and the patient's healthy tissues. The FIP protects normal cells from the harmful effects of chemotherapy while allowing the chemotherapeutic agent to maintain its anti-tumor activity, thereby resolving the contradiction between treatment efficacy and side effect severity
Solution Approach 2:
The patent converts the harmful effect of chemotherapy on healthy cells into a beneficial protective mechanism. By administering FIP, the harmful side effects are transformed into a controlled response where the immune system is modulated to protect healthy tissues while the chemotherapeutic agent continues to eliminate tumor cells
2Object-affected harmful factors
If current protective treatments are administered to reduce chemotherapy side effects, then some protection is provided, but the protection is inadequate and quality of life remains impacted
Solution Approach 1:
The patent changes the parameter of immune modulation by introducing FIP, which has specific immunomodulatory properties that differ from current protective treatments. This parameter change results in superior protection against side effects while maintaining or improving quality of life, as evidenced by restored blood cell levels and maintained intestinal villi integrity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
FIPs significantly reduce the severity of chemotherapy-induced side effects, including myelosuppression, mucositis, and osteoporosis, as demonstrated by restored blood cell levels, maintained intestinal villi integrity, and improved bone density, while maintaining quality of life and reducing cancer-related fatigue.
Implementation Method 1
The use of fungal immunomodulatory proteins (FIPs), such as FIP-gts and FIP-fve, in combination with chemotherapeutic agents like Docetaxel, to administer before, during, or after chemotherapy to reduce or prevent these adverse side effects by enhancing immune response and protecting tissues
Data Source
AI summary
The invention generally relates to an immunomodulatory protein and a chemotherapeutic agent for simultaneous, contemporaneous or sequential use in the treatment of diseases, more particularly of proliferative diseases, still more particularly of cancer(s), to a combination of an FIP and a chemotherapeutic agent, as well as to the medical and biotechnological applications thereof, more particularly in the field of the treatment of diseases, more particularly of proliferative diseases, still more particularly of cancer(s).